Afficher la notice abrégée

The 'normobaric oxygen paradox': does it increase haemoglobin?

dc.rights.licenseOTHen_US
dc.contributor.authorDe Bels, David
dc.contributor.authorTHEUNISSEN, Sigrid
dc.contributor.authorDevriendt, Jacques
dc.contributor.authorGERMONPRÉ, Peter
dc.contributor.authorLafère, Pierre
dc.contributor.authorValsamis, Joseph
dc.contributor.authorSNOECK, Thyl
dc.contributor.authorMeeus, Philippe
dc.contributor.authorBALESTRA, Costantino
dc.date.accessioned2021-01-27T16:00:52Z
dc.date.available2021-01-27T16:00:52Z
dc.date.issued2012-06-14
dc.identifier.issn1833-3516en_US
dc.identifier.urihttps://luck.synhera.be/handle/123456789/592
dc.description.abstractBackground: A novel approach to increasing erythropoietin (EPO) using oxygen (O2) (the 'normobaric oxygen paradox') has been reported in healthy volunteers. We investigated whether the EPO increase is sufficient to induce erythropoiesis by comparing two protocols of O2 administration. Methods: We compared the effect of daily versus alternate days 100% O2, breathed for 30 minutes, on haemoglobin concentrations during a 12-day period. Nine subjects underwent the two protocols six weeks apart. Results: We observed a significant increase in haemoglobin (as a percentage of baseline) in the alternate-days group compared to the daily group and to baseline after four days (105.5 ∓ 5.7 % vs. 99.6 ∓ 3.3 % difference from baseline; P < 0.01). At the end of the experimental period, haemoglobin values increased significantly compared to baseline in both groups. There was a significant percentage rise in reticulocyte count in the alternate-days group compared to the daily group (182 ∓ 94 % vs. 93 ∓ 34 %; P < 0.001). Conclusion: The normobaric oxygen paradox seems effective in increasing haemoglobin in non-anaemic, healthy volunteers, providing sufficient time is allowed between O2 applications. The exact time interval is not clearly defined by this study but should probably be at least or greater than two days. Further studies are needed to define more precisely clinical applications in the use of O2 as a pharmaceutical agent.en_US
dc.language.isoENen_US
dc.publisherEuropean Underwater and Baromedical Societyen_US
dc.relation.ispartofDiving and Hyperbaric Medicineen_US
dc.rights.urihttps://www.dhmjournal.com/images/Docs/Policies/2019-04-02_DHM_EmbargoImmediateReleasePolicy.pdfen_US
dc.subjectoxygenen_US
dc.subjecthaematologyen_US
dc.subjectReactive oxygen species (ROS)en_US
dc.subjectphysiologyen_US
dc.titleThe 'normobaric oxygen paradox': does it increase haemoglobin?en_US
dc.typeArticle scientifiqueen_US
synhera.classificationSciences de la santé humaineen_US
synhera.institutionHE Bruxelles Brabanten_US
synhera.otherinstitutionDepartment of Intensive Care Medicine, Brugmann University Hospital, Brussels, Belgium.en_US
synhera.otherinstitutionCenter for Hyperbaric Oxygen Therapy, Military Hospital "Queen Astrid"Brussels, Belgium.en_US
synhera.cost.total0en_US
synhera.cost.apc0en_US
synhera.cost.comp0en_US
synhera.cost.acccomp0en_US
dc.description.versionOuien_US
dc.rights.holderEuropean Underwater and Baromedical Societyen_US


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée